# HIV for NEET PG Microbiology: Structure, Entry, Natural History, NACO Strategy III Testing, Infant Diagnosis and India's 2024 Estimates

Source: https://tracknation.in/story/hiv-for-neet-pg-microbiology-structure-entry-natural-history-naco-strategy-iii-testing-infant-diagnosis-and-india-s-2024-estimates (TrackNation — free UPSC notes with PYQs)

> NEET PG Microbiology: HIV structure (gp120, gp41, p17, p24), entry via CD4 and CCR5/CXCR4, HIV-1 vs HIV-2, acute retroviral syndrome, CD4-linked opportunistic infections, NACO's three-test strategy, indeterminate results, early infant diagnosis by TNA PCR, TLD and Treat All, and India's HIV estimates, with a diagram, hooks, MCQs and cards.

## Start Here

🎯 **Exam priority: Very high.** *Expect: which HIV protein does what, co-receptors, HIV-2 features, when antibodies appear, CD4
thresholds for each opportunistic infection, NACO strategy III rules, why infants need PCR, the first-line regimen, and India's latest estimates.*

CBME mapping: **MI3.13, MI9.2**. Fact-checked against NACO testing (2024), treatment (2021) and estimation (2025) documents and the MSD Manual.

*HIV virology, natural history, testing and treatment. Drawn by TrackNation.*

## The Virus (NACO, MSD)

- HIV is a **lentivirus** ("slow virus"). Envelope **gp120** binds **CD4** and co-receptors; **gp41** is the
transmembrane protein that drives **fusion**; matrix **p17**; bullet-shaped core of **p24**.

- The core holds **two copies of positive-sense single-stranded RNA** and three enzymes — **reverse transcriptase, integrase and
protease**.

- Entry: gp120 binds CD4, then a **co-receptor (CCR5 or CXCR4)**; gp41 then fuses the envelope with the cell membrane.

- **HIV-1 and HIV-2** share routes and both cause AIDS, but HIV-2 has **slower progression** and **lower sexual and perinatal
transmission**.

## Natural History and Opportunistic Infections (MSD, NACO)

*Which opportunistic infections appear at which CD4 count, with NACO's action points. Drawn by TrackNation.*

- Primary infection may be silent or cause a transient **acute retroviral syndrome**; antibodies are usually measurable **within a few
weeks**.

- **AIDS**: serious opportunistic infection or cancer, or **CD4 <200/µL** (or CD4 <14%). NACO's **advanced HIV
disease**: CD4 <200 or WHO stage 3–4 in adults and children over 5; **all children under 5**.

- **CD4 <200**: **Pneumocystis pneumonia, toxoplasmic encephalitis, cryptococcal meningitis**. **CD4 <50**:
**CMV** and **MAC**.

- Vertical transmission: **in utero, at delivery, and through breastfeeding**.

## Testing in India (NACO HCTS 2024)

*NACO's three-test strategy for confirming HIV, step by step. Drawn by TrackNation.*

- **Strategy III** (general population, low prevalence, provider-initiated testing): **three different assays** that do not share
false reactivity, run in sequence. **Negative** if the first test is non-reactive; **positive only if all three are reactive**; in low
prevalence, two reactive tests give too low a positive predictive value.

- Screening anywhere; **confirmation at the ICTC** with three rapid tests. An **indeterminate** result → **fresh sample
after two weeks**.

- **Babies under 18 months**: antibody tests mislead because of **maternal anti-HIV IgG**; use **qualitative TNA PCR on
dried blood spots** (screening, then confirmatory PCR on a fresh DBS). A positive PCR at **6 weeks** indicates perinatal infection.

- Laboratory tools (MSD): antibody ± **p24 antigen** tests; **HIV RNA (viral load)** by nucleic acid amplification.

## Treatment and India's Numbers (NACO)

- **Treat All**: first-line **TLD** — tenofovir 300 + lamivudine 300 + **dolutegravir 50 mg** as one pill once daily;
**viral load** is the monitoring tool, baseline CD4 guides OI prophylaxis.

- **India 2024**: about **25.61 lakh PLHIV**; **adult prevalence 0.20%**; highest in Mizoram and Nagaland; between 2020 and 2024 new
infections fell 19.4% and vertical transmission rates 63.7%.

## Traps the Examiner Sets

- gp120 attaches; gp41 fuses; p24 is the core antigen.

- An antibody test in a baby under 18 months reflects the mother — use PCR.

- One non-reactive first test = negative; all three reactive = positive.

- PCP, toxoplasma and cryptococcus below 200; CMV and MAC below 50.

## Memory Hooks & Shortcuts

*Shortcuts to lock in this article's numbers and lists. Each one only re-packages facts proven above.*

- 🧠 **'120 grabs, 41 fuses, 24 is the core' — gp120, gp41, p24** — structure

- 🧠 **'Rapid Into Proteins' — Reverse transcriptase, Integrase, Protease** — enzymes

- 🧠 **'Two hundred: PCP, Toxo, Crypto; fifty: CMV and MAC'** — CD4

- 🧠 **Strategy III: 'One No = No; Three Yes = Yes'** — testing

- 🧠 **'Babies borrow Mum's antibodies — PCR them'** — infant diagnosis

## Rapid-Revision Cards

- 'Slow virus'.

- Binds CD4 + co-receptor.

- Fusion.

- Core; antigen tests.

- Matrix.

- 2 copies of +ssRNA.

- RT, integrase, protease.

- CCR5, CXCR4.

- Slower, less transmissible.

- Acute retroviral syndrome.

- CD4 <200 or OI/cancer.

- PCP, toxo, cryptococcus.

- CMV, MAC.

- 3 different assays.

- Test 1 non-reactive / all 3 reactive.

- Repeat in 2 weeks.

- TNA PCR on DBS.

- Perinatal infection.

- Tenofovir + lamivudine + dolutegravir.

- 25.61 lakh PLHIV; 0.20%.

- Mizoram, Nagaland.

## Sources

*Facts in this article were checked against these documents.*

- National HIV Counselling and Testing Services Guidelines — National AIDS Control Organisation, MoHFW, 2024

- National Guidelines for HIV Care and Treatment — National AIDS Control Organisation, MoHFW, 2021

- India HIV Estimates 2024: Fact Sheet — National AIDS Control Organisation and ICMR–NIMS, 2025

- MSD Manual Professional: Human Immunodeficiency Virus (HIV) Infection — Merck & Co. (MSD Manuals), 2024–26 (link)

- Competency Based Undergraduate Curriculum, Vol I: Microbiology (MI3.13, MI9.2) — National Medical Commission, 2024

## Test Yourself: Practice Questions

Thirty questions in NEET PG style, many of them programme and clinical scenarios.

## Practice Questions (NEET PG pattern)

*Original questions written in the style of the exam: +4 for a correct answer, −1 for a wrong one. Every answer
was checked against the sources listed above. NEET PG papers are not published by NBEMS, so these are not past-paper questions.*

**Q1.** HIV belongs to the lentiviruses, a name meaning

- (a) lethal virus

- (b) lymph virus

- (c) slow virus

- (d) lipid virus

**Answer: (c)** — NACO.

**Q2.** The HIV envelope protein that binds CD4 is

- (a) gp120

- (b) gp41

- (c) p24

- (d) p17

**Answer: (a)** — gp41 fuses.

**Q3.** The HIV protein that mediates fusion of envelope and cell membrane is

- (a) reverse transcriptase

- (b) p24

- (c) gp120

- (d) gp41

**Answer: (d)** — MSD.

**Q4.** The HIV core (capsid) protein detected in combined antigen–antibody tests is

- (a) p24

- (b) gp41

- (c) p17

- (d) gp160

**Answer: (a)** — NACO; MSD.

**Q5.** The HIV genome consists of

- (a) double-stranded DNA

- (b) two copies of positive-sense single-stranded RNA

- (c) segmented RNA

- (d) one negative-sense RNA

**Answer: (b)** — NACO.

**Q6.** The three enzymes inside the HIV core are

- (a) thymidine kinase, protease, lipase

- (b) reverse transcriptase, integrase and protease

- (c) DNA polymerase, helicase, ligase

- (d) neuraminidase, haemagglutinin, polymerase

**Answer: (b)** — Drug targets.

**Q7.** Besides CD4, HIV entry requires a co-receptor such as

- (a) CD8

- (b) CD21

- (c) MHC I

- (d) CCR5 or CXCR4

**Answer: (d)** — MSD.

**Q8.** Compared with HIV-1, HIV-2 shows

- (a) no AIDS

- (b) slower progression and less sexual and perinatal transmission

- (c) different transmission routes

- (d) faster progression

**Answer: (b)** — NACO.

**Q9.** A transient febrile illness weeks after exposure in primary HIV infection is

- (a) AIDS

- (b) acute retroviral syndrome

- (c) IRIS

- (d) seroreversion

**Answer: (b)** — MSD.

**Q10.** AIDS is defined by an opportunistic infection or cancer, or a CD4 count below

- (a) 50/µL

- (b) 200/µL

- (c) 350/µL

- (d) 500/µL

**Answer: (b)** — Or <14%.

**Q11.** With CD4 below 200/µL, the risk rises for

- (a) MAC only

- (b) CMV retinitis only

- (c) Pneumocystis pneumonia, toxoplasmic encephalitis and cryptococcal meningitis

- (d) no infections

**Answer: (c)** — MSD.

**Q12.** CMV retinitis and disseminated MAC typically occur when CD4 falls below

- (a) 200/µL only

- (b) 500/µL

- (c) 350/µL

- (d) 50/µL

**Answer: (d)** — MSD.

**Q13.** Under NACO strategy III, a person is reported HIV-negative when

- (a) two tests are non-reactive

- (b) the third test is non-reactive

- (c) any one of three tests is non-reactive

- (d) the first test is non-reactive

**Answer: (d)** — NACO.

**Q14.** Under strategy III, HIV-positive status requires

- (a) one reactive test

- (b) reactivity on all three different assays

- (c) two reactive tests

- (d) Western blot

**Answer: (b)** — NACO.

**Q15.** Three tests are needed in low-prevalence settings because

- (a) the positive predictive value of two tests is too low

- (b) HIV-2 is common

- (c) antibodies appear late

- (d) tests are cheap

**Answer: (a)** — NACO.

**Q16.** The three assays used in strategy III must

- (a) all be Western blots

- (b) be different and not share the same false reactivity

- (c) be PCR tests

- (d) be the same kit repeated

**Answer: (b)** — NACO.

**Q17.** An indeterminate HIV antibody result at the ICTC should be followed by

- (a) immediate ART

- (b) a CD4 count

- (c) declaring negative

- (d) a fresh sample after two weeks

**Answer: (d)** — NACO.

**Q18.** Confirmation of HIV diagnosis in asymptomatic people is done at the

- (a) ART centre with viral load

- (b) PHC with one test

- (c) ICTC with three rapid tests

- (d) blood bank

**Answer: (c)** — NACO.

**Q19.** Antibody tests cannot diagnose HIV in a 6-month-old born to an HIV-positive mother because

- (a) p24 is absent

- (b) infants make no antibodies

- (c) maternal anti-HIV IgG is present

- (d) the virus is absent in blood

**Answer: (c)** — Use PCR.

**Q20.** Early infant diagnosis under NACO uses

- (a) CD4 count

- (b) rapid antibody tests

- (c) qualitative TNA PCR on dried blood spots

- (d) Western blot

**Answer: (c)** — Confirm on fresh DBS.

**Q21.** A positive HIV PCR at 6 weeks of age indicates

- (a) false positive always

- (b) perinatal infection

- (c) HIV-2 only

- (d) maternal antibody

**Answer: (b)** — NACO.

**Q22.** Vertical HIV transmission can occur

- (a) only during delivery

- (b) only in utero

- (c) only through breastfeeding

- (d) in utero, during delivery and through breastfeeding

**Answer: (d)** — NACO; MSD.

**Q23.** The preferred first-line ART regimen in India is

- (a) zidovudine monotherapy

- (b) nevirapine-based

- (c) TLD: tenofovir, lamivudine and dolutegravir in one pill

- (d) protease inhibitor alone

**Answer: (c)** — NACO 2021.

**Q24.** Under 'Treat All', the main tool for monitoring ART response is

- (a) ESR

- (b) CD4 alone

- (c) p24 antigen

- (d) viral load

**Answer: (d)** — NACO.

**Q25.** NACO defines advanced HIV disease in all

- (a) pregnant women

- (b) HIV-2 infections

- (c) children under 5 years with HIV

- (d) adults with CD4 above 500

**Answer: (c)** — Adults: CD4 <200 or stage 3–4.

**Q26.** India's estimated number of people living with HIV in 2024 was about

- (a) 25.61 lakh

- (b) 50 lakh

- (c) 1 crore

- (d) 2.5 lakh

**Answer: (a)** — NACO 2025.

**Q27.** India's adult HIV prevalence in 2024 was estimated at

- (a) 1%

- (b) 0.02%

- (c) 2%

- (d) 0.20%

**Answer: (d)** — NACO.

**Q28.** Between 2020 and 2024, India's vertical transmission rate fell by about

- (a) 5%

- (b) 19.4%

- (c) 100%

- (d) 63.7%

**Answer: (d)** — New infections −19.4%.

**Q29.** The states with the highest adult HIV prevalence in India are

- (a) Mizoram and Nagaland

- (b) Punjab and Haryana

- (c) Bihar and UP

- (d) Kerala and Goa

**Answer: (a)** — NACO estimates.

**Q30.** HIV viral load is measured by

- (a) rapid antibody test

- (b) CD4 count

- (c) Western blot

- (d) nucleic acid amplification of HIV RNA

**Answer: (d)** — MSD.

### Active Recall

From memory: describe HIV structure, genome and entry, compare HIV-1 and HIV-2, outline natural history and CD4-linked infections, explain NACO strategy III and its interpretation, how infants are diagnosed, the first-line regimen and India's 2024 estimates.
